RLDC 2006 - Fourth Annual Pulmonary
Alveolar Proteinosis Research Conference
AND PAP PATIENT  EDUCATION MEETING

Westin Hotel, Cincinnati, Ohio

Friday, March 31 – Sunday, April 2, 2006

Friday Morning, March 31st

Session I, PAP Patient Meeting, Chair, Colleen Morone & Jon Pulchalski, MD            Westin - Harrison

     9:00  -   9:30     Welcome & Introduction

    9:30  -  11:30     Achieving advocacy for PAP Patients

   12:00  -   1:00     Lunch                                                                                        Westin - Presidential I

Friday Afternoon, 1:00 pm - 5:30 pm                                                                      Westin - Taft II

Session II - PAP, Clinical Science: Chair, James Ellis, MD

    1:00  -   1:05     Comments by Chair, James Ellis/Patient intro

    1:05  -   1:15     Patient Speaker

    1:15  -   1:35     Yoshikazu Inoue, MD, PhD - "Longitudinal Follow-Up Study of PAP Patients in Japan"

    1:35  -   1:55     Maurizio Luisetti, MD - "Longitudinal Follow-Up Study of PAP Patients in Italy"

    1:55  -   2:15     Haruyuki Ishii, MD - "Clinical Features of Anti-GM-CSF Antibody Negative PAP Patients"

    2:15  -   2:35     Mani Kavuru, MD - "Evaluation of Subcutaneous GM-CSF Therapy for PAP in USA"

    2:35  -   2:55     Koh Nakata, MD, PhD - "Evaluation of Aerosolized GM-CSF Therapy for PAP in Japan"

    2:55  -   3:10     Break

Session III - PAP, Basic Science: Chair, Toshihiro Nukiwa, MD, PhD                               Westin - Taft II

    3:10  -   3:15     Comments by Chair, Toshihiro Nukiwa/Patient intro

    3:15  -   3:25     Patient Speaker

    3:25  -   3:40     Tracy Bonfield, PhD - Title to be determined

    3:40  -   3:55     Hiroko Kanazawa, PhD - "Immunological abnormality in the blood of idiopathic PAP"

    3:55  -   4:10     Mary-Jane Thommason, PhD - Title to be determined

    4:10  -   4:25     Haruko Iwabuchi, MD - "PAP-like alveolar macrophages in new-born rats"

    4:25  -   4:40     Masato Watanabe, MD, PhD - "Anti-cytokine antibodies in PAP and healthy individuals"

    4:40  -   4:55     David Beck, MD - "Recapitulating PAP in non-human primates"

    4:55  -   5:10     Kanji Uchida, MD, PhD - "Anti-GM-CSF antibodies in healthy individuals"

    5:10  -   5:25     Abstract/To be determined

Friday Evening, 6:30 pm - 8:00 pm                                        Westin - Presidential Ballroom

RLDC Combined Investigator's & Patient's Dinner

     6:00 -    7:00   Welcome Reception / Hors d'oeuvres

     7:00 -    8:30    Dinner & Dessert

     8:30 -  10:00    Free time for discussion

Saturday Morning, April 1st

Session IV, PAP Patient Workshop, Chairs, Colleen Morone & Dave Beck, MD         Westin - Harrison
 

     7:30 –   8:00    Continental Breakfast

    9:00  - 11:30     Developing education materials for PAP patients

Saturday Afternoon, 1:00 pm - 5:30 pm                                                               Westin - Taft II

Session V - Workshop, Developing New/Better Therapies for PAP: Chair, Mani Kavuru, MD

    2:00  -   2:05     Comments by Chair, Mani Kavuru/Patient intro

    2:05  -   2:15     Patient Speaker

    2:15  -   2:35     Bruce Trapnell, MD, "Proposed PAP Longitudinal Study Design"

    2:35  -   4:10     Round Table Discussion - no formal presentations

    2:35  -   2:55     "How and when should whole lung lavage be used in the treatment of PAP?"

    2:55  -   3:15     "How and when should GM-CSF be used in the treatment of PAP?"

    3:15  -   3:35     "How and when should plasmapheresis be used in the treatment of PAP?"

    3:35  -   3:55     "Progress towards clinical evaluation of Rituximab as a treatment for PAP"

    3:55  -   4:10     Break

Session VI - Workshop, Harmonizing Clinical Assessment of PAP                      Westin - Taft II

Chair, Cliff Morgan, MD  

    4:10  -   5:30     Round Table Discussion - no formal presentations

    4:10  -   4:25     How should the diagnosis of primary (idiopathic) PAP be made in 2006?

    4:25  -   4:40     How should the severity of lung disease in primary PAP be judged?

    4:40  -   4:55     What are the indications for therapy for primary PAP, and Is there consensus?

    4:55  -   5:10     What is the best nomenclature for the various forms of PAP?

    5:10  -   5:25     Standardizing Anti-GM-CSF Antibody Titer Methods"

Patient Session III, PAP Patient Workshop: Chair, Louie Schimpf                        Westin - Harrison

    4:00  -   5:30     Assessing quality of life in PAP clinical research studies

Saturday Evening, 6:30 pm - 9:00 pm                                                                      Westin - Hayes

PAP Foundation Dinner & Board Meeting: Chairs, Louie Schimpf & Bruce Trapnell, MD

     6:30 -    7:30    Dinner

     7:30 -    9:00    PAP Foundation Board Meeting